Drug interactions
Bosentan + Erdafitinib
Severity: Moderate
Bosentan and Erdafitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib is cleared by CYP2C9 and CYP3A4, and bosentan induces both pathways. Reduced erdafitinib exposure may lessen efficacy in urothelial cancer.
What this interaction means in plain words
Bosentan and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Bosentan belongs to Miscellaneous; Erdafitinib belongs to Oncology.
Why it happens
Bosentan induces CYP2C9 and CYP3A4, increasing erdafitinib clearance.
What to do
Avoid combination if possible and monitor tumour response; erdafitinib dose is guided by serum phosphate rather than being adjusted for inducers.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Erdafitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Bosentan
- Bosentan + Cyclosporin Contraindicated
- Bosentan + Glibenclamide Contraindicated
- Bosentan + Glyburide-metformin Contraindicated
- Bosentan + Lonafarnib Contraindicated
- Bosentan + Sparsentan Contraindicated
- Artemether / lumefantrine + Bosentan Major
Other interactions of Erdafitinib
Frequently asked questions
Can I take Bosentan with Erdafitinib?
MediHelp rates the interaction as moderate. Bosentan and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib is cleared by CYP2C9 and CYP3A4, and bosentan induces both pathways. Reduced erdafitinib exposure may lessen efficacy in urothelial cancer.
How serious is the interaction between Bosentan and Erdafitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combination if possible and monitor tumour response; erdafitinib dose is guided by serum phosphate rather than being adjusted for inducers.
What other medicines interact with Bosentan?
MediHelp also lists interactions of Bosentan with, for example, Cyclosporin, Glibenclamide, Glyburide-metformin. The full list is on the Bosentan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
